Effects of Stent Coating on Platelets and Endothelial Cells After Intracoronary Stent Implantation

Overview

Journal Clin Cardiol

Specialty Cardiology & Vascular Diseases

Date 2001 Feb 24

PMID 11214746

Citations 3

Authors

E Atalar

I Haznedaroglu

K Aytemir

S Aksoyek

K Ovunc

A Oto

F Ozmen

Affiliations

Soon will be listed here.

Abstract

Background: Adhesion molecules are known to be important in the regulation of endothelial cell and platelet functions. Increased platelets P-selectin expression is a marker of stent thrombosis after uncoated stent placement.

Hypothesis: The aim of this study was to compare the effects of intracoronary placement of phosphorylcholine (PC)-coated, versus heparin-coated, versus uncoated stents on platelets and endothelial activity.

Methods: Thirty patients (age 55 +/- 10, 27 men) with significant proximal left anterior descending coronary artery stenoses were randomized to elective implantation of PC-coated, versus heparin-coated, versus uncoated stents. Following stent placement, intravenous heparin and aspirin plus ticlopidine were administered. Venous plasma soluble E-selectin, sP-selectin, and intercellular adhesion molecule-l levels were measured before the procedure and 24 and 48 h thereafter as markers of platelet and endothelial cell activation. Patients were excluded if they had a disease known to influence platelet and endothelial cell function.

Results: Plasma sP-selectin levels decreased significantly after implantation of PC- and heparin-coated stents (p = 0.04), but remained unchanged in patients randomized to uncoated stents. Plasma sE-selectin levels increased significantly after uncoated stent placement (p = 0.04) and remained unchanged after coated stent implantation.

Conclusion: In patients treated with combined antiplatelet therapy, implantation of PC- and heparin-coated stents decreased platelet activity without activating endothelial cells, whereas placement of uncoated stents led to endothelial activation without changing platelet activity. These results suggest that PC-coated and heparin-coated stents may be advantageous in limiting thrombotic complications.

Citing Articles

Safety and Efficacy of the Endeavor Resolute® Stent in Patients with Multivessel Disease: The HEART (Honam EndeAvor ResoluTe) Prospective, Multicenter Trial.

Sim D, Jeong M, Hong Y, Kim J, Ahn Y, Park K Chonnam Med J. 2018; 54(1):55-62.

PMID: 29399567 PMC: 5794480. DOI: 10.4068/cmj.2018.54.1.55.

Ultra-hydrophilic stent platforms promote early vascular healing and minimise late tissue response: a potential alternative to second-generation drug-eluting stents.

Kolandaivelu K, Bailey L, Buzzi S, Zucker A, Milleret V, Ziogas A EuroIntervention. 2016; 12(17):2148-2156.

PMID: 27993749 PMC: 6563826. DOI: 10.4244/EIJ-D-15-00497.

Coronary stents: in these days of climate change should all stents wear coats?.

Lowe R, Menown I, Nogareda G, Penn I Heart. 2005; 91 Suppl 3:iii20-3.

PMID: 15919648 PMC: 1876356. DOI: 10.1136/hrt.2005.060269.

References

Kurz R, Graf B, Gremmel F, Wurnig C, Stockenhuber F . Increased serum concentrations of adhesion molecules after coronary angioplasty. Clin Sci (Lond). 1994; 87(6):627-33. DOI: 10.1042/cs0870627. View

Hardhammar P, van Beusekom H, Emanuelsson H, Hofma S, Albertsson P, Verdouw P . Reduction in thrombotic events with heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries. Circulation. 1996; 93(3):423-30. DOI: 10.1161/01.cir.93.3.423. View

Gasperetti C, Gonias S, Gimple L, Powers E . Platelet activation during coronary angioplasty in humans. Circulation. 1993; 88(6):2728-34. DOI: 10.1161/01.cir.88.6.2728. View

Eeckhout E, Kappenberger L, Goy J . Stents for intracoronary placement: current status and future directions. J Am Coll Cardiol. 1996; 27(4):757-65. DOI: 10.1016/0735-1097(95)00548-4. View

Siminiak T, Dye J, Egdell R, More R, Wysocki H, Sheridan D . The release of soluble adhesion molecules ICAM-1 and E-selectin after acute myocardial infarction and following coronary angioplasty. Int J Cardiol. 1997; 61(2):113-8. DOI: 10.1016/s0167-5273(97)00161-7. View

Jang Y, Lincoff A, Plow E, Topol E . Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol. 1994; 24(7):1591-601. DOI: 10.1016/0735-1097(94)90162-7. View

Serruys P, Van Hout B, Bonnier H, Legrand V, Garcia E, Macaya C . Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet. 1998; 352(9129):673-81. DOI: 10.1016/s0140-6736(97)11128-x. View

Inoue T, Sakai Y, Morooka S, Hayashi T, Takayanagi K, Takabatake Y . Expression of polymorphonuclear leukocyte adhesion molecules and its clinical significance in patients treated with percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1996; 28(5):1127-33. DOI: 10.1016/S0735-1097(96)00308-7. View

Arnaout M . Cell adhesion molecules in inflammation and thrombosis: status and prospects. Am J Kidney Dis. 1993; 21(1):72-6. DOI: 10.1016/s0272-6386(12)80725-6. View

10.

Carlos T, Harlan J . Leukocyte-endothelial adhesion molecules. Blood. 1994; 84(7):2068-101. View

11.

Neumann F, Ott I, Gawaz M, PUCHNER G, Schomig A . Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplasty. J Am Coll Cardiol. 1996; 27(4):819-24. DOI: 10.1016/0735-1097(95)00563-3. View

12.

Neumann F, Gawaz M, Dickfeld T, Wehinger A, Walter H, BLASINI R . Antiplatelet effect of ticlopidine after coronary stenting. J Am Coll Cardiol. 1997; 29(7):1515-9. DOI: 10.1016/s0735-1097(97)00073-9. View

13.

Rupprecht H, Darius H, Borkowski U, Voigtlander T, Nowak B, Genth S . Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation. Circulation. 1998; 97(11):1046-52. DOI: 10.1161/01.cir.97.11.1046. View

14.

Zheng H, Barragan P, Corcos T, Simeoni J, Favereau X, Roquebert P . Clinical experience with a new biocompatible phosphorylcholine-coated coronary stent. J Invasive Cardiol. 2000; 11(10):608-14. View

15.

Piovella F, Ricetti M, Almasio P, Samaden A, SEMINO G, Ascari E . The effect of ticlopidine on human endothelial cells in culture. Thromb Res. 1984; 33(3):323-32. DOI: 10.1016/0049-3848(84)90167-1. View

16.

Pepine C, Holmes Jr D . Coronary artery stents. American College of Cardiology. J Am Coll Cardiol. 1996; 28(3):782-94. View

17.

Balcon R, Beyar R, Chierchia S, De Scheerder I, Hugenholtz P, Kiemeneij F . Recommendations on stent manufacture, implantation and utilization. Study Group of the Working Group on Coronary Circulation. Eur Heart J. 1997; 18(10):1536-47. DOI: 10.1093/oxfordjournals.eurheartj.a015133. View

18.

Gawaz M, Neumann F, Ott I, May A, Rudiger S, Schomig A . Role of activation-dependent platelet membrane glycoproteins in development of subacute occlusive coronary stent thrombosis. Coron Artery Dis. 1997; 8(3-4):121-8. DOI: 10.1097/00019501-199703000-00001. View

19.

Mak K, Belli G, ELLIS S, Moliterno D . Subacute stent thrombosis: evolving issues and current concepts. J Am Coll Cardiol. 1996; 27(2):494-503. DOI: 10.1016/0735-1097(95)00466-1. View

20.

Yang L, Hoppensteadt D, Fareed J . Modulation of vasoconstriction by clopidogrel and ticlopidine. Thromb Res. 1998; 92(2):83-9. DOI: 10.1016/s0049-3848(98)00114-5. View